MIRCERA.com

MIRCERA – through its different receptor interaction and longer half-life – delivers sustained anaemia management.

 

Achieves target haemoglobin levels  
Target Hb levels were achieved in up to 97.5% of patients not on dialysis treated with subcutaneous (SC) MIRCERA (dosed every 2 weeks) and in up to 93.3% of patients on dialysis with intravenous (IV) MIRCERA.^1–3

 

Smooth and steady rise in haemoglobin levels
MIRCERA provides a smooth and steady rise in Hb levels (see Figure), minimising the risk of exceeding a rate of increase greater than 2 g/dL in 1 month.^1–3 

 

 

Mean haemoglobin levels in patients with chronic kidney disease not on dialysis during correction and evaluation phase of treatment with MIRCERA or darbepoetin alfa.¹

 

Stable and sustained haemoglobin levels  
MIRCERA IV or SC also provides Hb stability during maintenance therapy with once-monthly dosing.^4–11 Stable and sustained Hb levels can be achieved regardless of age, gender, comorbidities, or chronic kidney disease stage.^4–11 Once-monthly MIRCERA maintenance therapy keeps average Hb levels within a range of 11–12 g/dL (see Figure).^8–11

 

 

Mean haemoglobin (Hb) levels in patients receiving once-monthly intravenous (IV) or subcutaneous (SC) MIRCERA.^5,7,8–11

 

References:

 

1. Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anaemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial. Clin J Am Soc Nephrol. 2007 In press.
2. Klinger M, Aria M, Vargemezis V, et al. Intravenous C.E.R.A. administered twice monthly corrects haemoglobin levels in patients with chronic kidney disease on dialysis: results of AMICUS, a randomized prospective study vs epoetin given once to three times weekly. Am J Kidney Dis. 2007 In press.
3. MIRCERA® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.
4. Levin NW, Imbasciati E, Combe C, et al. Adequate Hb levels are maintained with IV C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status. J Am Soc Nephrol. 2006;17:619A (abstract SA-PO206).
5. Ryckelynck J-P, Harris K, Selga R, et al. SC C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status. J Am Soc Nephrol. 2006;17:620A (abstract SA-PO210).
6. Imbasciati E, Bernado M, Caraman P-L, et al. Stable haemaoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis with varying C-reactive protein (CRP), albumin or dialysis adequacy. Nephrol Dial Transplant. 2007 In Press (abstract Suo005).
7. Mann J, Locatelli F, Sulowicz W, et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly. Nephrol Dial Transplant. 2007 In Press (abstract Suo002).
8. Sulowicz W, Locatelli F, Ryckelynck J-P, et al. Once-monthly subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) maintains stable control in patients with chronic kidney disease on dialysis directly converted from epoetin one to three times weekly. Clin J Amer Soc Nephrol. 2007 doi:10.2215/CJN.03631006.
9. Canaud B, Mingardi G, Braun J, et al., on behalf of the ARCTOS Study Investigators.  Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin: results from STRIATA, a randomized phase III study. 2007 Submitted.
10. Locatelli F, Sulowicz W, Harris K, et al.SC C.E.R.A. (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1–3 times per week in patients with CKD on dialysis. J Am Soc Nephrol 2006;17:619A.
11. Fishbane S, Levin NW, Mann JFE, et al. IV C.E.R.A. (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1–3 times per week in patients with CKD on dialysis. J Am Soc Nephrol 2006;17:618A (abstract SA-PO205).